HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
This article was originally published in The Pink Sheet Daily
Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.
You may also be interested in...
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.